Lilach Goldstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lilach Goldstein has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Firas Fahoum
EEG and Epilepsy Unit, Department of Neurology Tel Aviv Sourasky Medical Center Tel Aviv Israel
10 shared publications - Inbal Maidan
EEG and Epilepsy Unit, Department of Neurology Tel Aviv Sourasky Medical Center Tel Aviv Israel
3 shared publications - Michael R. Sperling
Farber Institute for Neuroscience, Department of Neurology, Thomas Jefferson University, Philadelphia, USA
3 shared publications - Alon Doron
Gray Faculty of Medical and Health Science, Tel Aviv University , Tel Aviv
2 shared publications - Guy Gurevitch
Sagol Brain Institute, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel
2 shared publications - Ido Strauss
Gray Faculty of Medical and Health Sciences Tel Aviv University Tel Aviv Israel
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Wiley in Epilepsia Open
Stability of the Epileptogenic Index across seizures and the effects of sleep and withdrawal of anti‐seizure medications
Objective: Epileptogenic Index (EI) is a promising index to evaluate the epileptogenicity of the brain tissue and is useful in planning epilepsy surgery. We aimed to evaluate whether EI maps are consistent across seizures within patients and whether EI‐derived measures are affected by the vigilance state and anti‐seizure medication (ASM) dose. Methods: We analyzed 127 stereoelectroencephalography (SEEG) seizures from 19 patients. EI was calculated in all seizures. Within‐patient EI consistency was assessed using pairwise Spearman correlations between seizure‐specific EI maps. To assess the effects of vigilance and ASM on EI consistency, we calculated a contact‐level p _weighted EI score that combines the frequency of suprathreshold EI involvement and mean EI magnitude, separately across vigilance states and in a subset of patients with different ASM states. Results: Mean seizure‐to‐seizure EI correlations ranged from 0.11 to 0.81, indicating substantial variability in within‐patient EI consistency. Seven patients showed high consistency (≥0.6) and four showed low consistency (≤0.3). At the contact level, no differences in p _weighted EI were found between wakefulness and sleep. In contrast, p _weighted EI was significantly higher during reduced ASM compared with full ASM doses. Significance: EI maps are not uniformly stable across seizures. ASM reduction may broaden or intensify EI‐defined epileptogenic involvement, suggesting that ASM status should be considered when interpreting EI during SEEG evaluation. These findings are hypothesis‐generating and require prospective validation to determine their clinical utility for surgical planning. Plain Language Summary: The Epileptogenic Index (EI) measures the involvement of a recorded brain area during a specific seizure. This study shows that EI patterns can vary significantly between different seizures in the same patient. While sleep states do not change these patterns, reducing a patient's anti‐seizure medications increases EI values, making seizures appear to spread more broadly. These medication‐induced changes must be carefully considered to accurately map the epileptic network for surgical decisions.
- 23 October 2026
- Published by Wiley in Epilepsia Open
Open AccessStability of the Epileptogenic Index across seizures and the effects of sleep and withdrawal of anti‐seizure medications
Objective: Epileptogenic Index (EI) is a promising index to evaluate the epileptogenicity of the brain tissue and is useful in planning epilepsy surgery. We aimed to evaluate whether EI maps are consistent across seizures within patients and whether EI‐derived measures are affected by the vigilance state and anti‐seizure medication (ASM) dose. Methods: We analyzed 127 stereoelectroencephalography (SEEG) seizures from 19 patients. EI was calculated in all seizures. Within‐patient EI consistency was assessed using pairwise Spearman correlations between seizure‐specific EI maps. To assess the effects of vigilance and ASM on EI consistency, we calculated a contact‐level p _weighted EI score that combines the frequency of suprathreshold EI involvement and mean EI magnitude, separately across vigilance states and in a subset of patients with different ASM states. Results: Mean seizure‐to‐seizure EI correlations ranged from 0.11 to 0.81, indicating substantial variability in within‐patient EI consistency. Seven patients showed high consistency (≥0.6) and four showed low consistency (≤0.3). At the contact level, no differences in p _weighted EI were found between wakefulness and sleep. In contrast, p _weighted EI was significantly higher during reduced ASM compared with full ASM doses. Significance: EI maps are not uniformly stable across seizures. ASM reduction may broaden or intensify EI‐defined epileptogenic involvement, suggesting that ASM status should be considered when interpreting EI during SEEG evaluation. These findings are hypothesis‐generating and require prospective validation to determine their clinical utility for surgical planning. Plain Language Summary: The Epileptogenic Index (EI) measures the involvement of a recorded brain area during a specific seizure. This study shows that EI patterns can vary significantly between different seizures in the same patient. While sleep states do not change these patterns, reducing a patient's anti‐seizure medications increases EI values, making seizures appear to spread more broadly. These medication‐induced changes must be carefully considered to accurately map the epileptic network for surgical decisions.
- Open Access
- 1 October 2026
- Published by Elsevier in Clinical Neurophysiology
- Vol. 193, 2112430
Clinical validation of autoSCORE: A human-in-the-loop AI tool for interpretation of long-term EEG recordings
- 1 October 2026
- Published by Elsevier in Clinical Neurophysiology
- Vol. 193, 2112430
Open AccessClinical validation of autoSCORE: A human-in-the-loop AI tool for interpretation of long-term EEG recordings
- Open Access
- 29 August 2026
- Published by Wiley in Epileptic Disorders
Localizing value of ictal déjà vu, déjà vécu, dreamy state and reminiscence: A systematic review
We performed a systematic review of the literature regarding the localization value of déjà vu (DV), déjà vécu, dreamy state and reminiscence in focal epilepsy, with the aim to summarize the state‐of‐the‐art anatomo‐electroclinical correlations in the field and help guide interpretation of ictal semiology within the framework of pre‐surgical evaluation of focal drug‐resistant epilepsy (DRE). The review was performed according to Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA) statement. Patient series were included if they provided sufficient anatomo‐electroclinical correlation to allow determination of the epileptogenic zone (EZ) and assessment of the level of confidence in each report. We evaluated the risk of bias and the diagnostic accuracy quality of each publication using the Quality of Diagnostic Accuracy Studies (QUADAS‐2) and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tools. For search terms déjà, dreamy state and reminiscence, we identified 22 eligible publications containing a total of 597 patients. The reports with the highest level of confidence suggest that ictal DV or dreamy state reflect an EZ located in both anterior and posterior mesial temporal structures; however, lateral temporal and insulo‐opercular EZs have also been described. The anatomo‐electroclinical correlation of ictal DV and related phenomena points most commonly to the mesial temporal structures; however, due to the heterogeneous quality of reports and the pooling and overlap of these related symptoms, our findings are regarded with moderate degree of reliability. Future reports should adopt a more refined classification and clinical description of these experiential memory‐related ictal phenomena. The use of advanced imaging modalities and a broader implementation of stereoelectroencephalography should facilitate the accumulation of cases with higher level of evidence, which would result in a more robust anatomo‐electroclinical correlations of these fascinating epileptic semiologies.
- 29 August 2026
- Published by Wiley in Epileptic Disorders
Open AccessLocalizing value of ictal déjà vu, déjà vécu, dreamy state and reminiscence: A systematic review
We performed a systematic review of the literature regarding the localization value of déjà vu (DV), déjà vécu, dreamy state and reminiscence in focal epilepsy, with the aim to summarize the state‐of‐the‐art anatomo‐electroclinical correlations in the field and help guide interpretation of ictal semiology within the framework of pre‐surgical evaluation of focal drug‐resistant epilepsy (DRE). The review was performed according to Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA) statement. Patient series were included if they provided sufficient anatomo‐electroclinical correlation to allow determination of the epileptogenic zone (EZ) and assessment of the level of confidence in each report. We evaluated the risk of bias and the diagnostic accuracy quality of each publication using the Quality of Diagnostic Accuracy Studies (QUADAS‐2) and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tools. For search terms déjà, dreamy state and reminiscence, we identified 22 eligible publications containing a total of 597 patients. The reports with the highest level of confidence suggest that ictal DV or dreamy state reflect an EZ located in both anterior and posterior mesial temporal structures; however, lateral temporal and insulo‐opercular EZs have also been described. The anatomo‐electroclinical correlation of ictal DV and related phenomena points most commonly to the mesial temporal structures; however, due to the heterogeneous quality of reports and the pooling and overlap of these related symptoms, our findings are regarded with moderate degree of reliability. Future reports should adopt a more refined classification and clinical description of these experiential memory‐related ictal phenomena. The use of advanced imaging modalities and a broader implementation of stereoelectroencephalography should facilitate the accumulation of cases with higher level of evidence, which would result in a more robust anatomo‐electroclinical correlations of these fascinating epileptic semiologies.
- Open Access
- 12 December 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 175, 110858
Dose adjustment of the anti-seizure medications levetiracetam and lamotrigine during the postpartum period. Schedule plan, safety and efficacy
- 12 December 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 175, 110858
Open AccessDose adjustment of the anti-seizure medications levetiracetam and lamotrigine during the postpartum period. Schedule plan, safety and efficacy
- Open Access
- 7 August 2025
- Published by Wiley in Epilepsia Open
- Vol. 10 (5) , 1532-1544
Enhanced response inhibition in patients with drug‐resistant juvenile myoclonic epilepsy: Event‐related potentials evidence of excitatory–inhibitory imbalance
Objective: To investigate the excitatory–inhibitory imbalance in drug‐resistant Juvenile Myoclonic Epilepsy (DR‐JME) patients using event‐related potentials during motor and cognitive tasks. Methods: Eighteen JME patients and 11 healthy controls performed a visual Go No‐Go task while sitting (single‐task) and walking (dual‐task). EEG signals were analyzed using frequency‐domain techniques. Nonparametric tests compared groups and conditions. Results: JME patients showed worse performance and slower reaction times than healthy controls ( p < 0.04). DR‐JME patients demonstrated worse performance during Go cues ( p = 0.001) but better withdrawal response to No‐Go cues ( p = 0.03) compared to drug‐respondent JME. Significant differences in EEG spectral power were observed, particularly during dual‐task conditions. JME patients had lower power in the delta and alpha frequency bands compared to controls ( p < 0.03). DR‐JME patients showed lower power in theta, alpha, and beta bands during dual‐task Go cues ( p < 0.003) but higher power during dual‐task No‐Go cues compared to drug‐respondent JME ( p < 0.02). Significance: DR‐JME patients exhibited enhanced response inhibition, especially under dual‐task conditions, which likely indicates maladaptive neural processing and supports the notion of an excitatory–inhibitory imbalance in DR‐JME. This study provides new insights into the neurophysiological basis of drug resistance in JME, revealing distinct patterns of brain activity associated with inhibitory control. These findings could provide valuable insights into understanding the complex interactions between neuronal excitation and inhibition. Plain Language Summary: Some patients with Juvenile Myoclonic Epilepsy (JME) do not respond to medication, but the reasons remain unclear. This study found that drug‐resistant JME patients show distinct brain activity and behavioral patterns, particularly during tasks requiring attention and movement. They had slower reactions but showed better inhibition to stop responses, along with altered brain rhythms, especially under dual‐task conditions. These results suggest an imbalance between brain excitation and inhibition, offering new insights into the neural mechanisms behind drug resistance in JME.
- 7 August 2025
- Published by Wiley in Epilepsia Open
- Vol. 10 (5) , 1532-1544
Open AccessEnhanced response inhibition in patients with drug‐resistant juvenile myoclonic epilepsy: Event‐related potentials evidence of excitatory–inhibitory imbalance
Objective: To investigate the excitatory–inhibitory imbalance in drug‐resistant Juvenile Myoclonic Epilepsy (DR‐JME) patients using event‐related potentials during motor and cognitive tasks. Methods: Eighteen JME patients and 11 healthy controls performed a visual Go No‐Go task while sitting (single‐task) and walking (dual‐task). EEG signals were analyzed using frequency‐domain techniques. Nonparametric tests compared groups and conditions. Results: JME patients showed worse performance and slower reaction times than healthy controls ( p < 0.04). DR‐JME patients demonstrated worse performance during Go cues ( p = 0.001) but better withdrawal response to No‐Go cues ( p = 0.03) compared to drug‐respondent JME. Significant differences in EEG spectral power were observed, particularly during dual‐task conditions. JME patients had lower power in the delta and alpha frequency bands compared to controls ( p < 0.03). DR‐JME patients showed lower power in theta, alpha, and beta bands during dual‐task Go cues ( p < 0.003) but higher power during dual‐task No‐Go cues compared to drug‐respondent JME ( p < 0.02). Significance: DR‐JME patients exhibited enhanced response inhibition, especially under dual‐task conditions, which likely indicates maladaptive neural processing and supports the notion of an excitatory–inhibitory imbalance in DR‐JME. This study provides new insights into the neurophysiological basis of drug resistance in JME, revealing distinct patterns of brain activity associated with inhibitory control. These findings could provide valuable insights into understanding the complex interactions between neuronal excitation and inhibition. Plain Language Summary: Some patients with Juvenile Myoclonic Epilepsy (JME) do not respond to medication, but the reasons remain unclear. This study found that drug‐resistant JME patients show distinct brain activity and behavioral patterns, particularly during tasks requiring attention and movement. They had slower reactions but showed better inhibition to stop responses, along with altered brain rhythms, especially under dual‐task conditions. These results suggest an imbalance between brain excitation and inhibition, offering new insights into the neural mechanisms behind drug resistance in JME.
- Open Access
- 27 June 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 173
Stress and seizures: The October 7th experience
- 27 June 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 173
Open AccessStress and seizures: The October 7th experience
Real‐world use of cenobamate in adults: Efficacy and predictors of treatment response
Objective: This study assesses the efficacy, safety, and tolerability of cenobamate using long‐term real‐world data, incorporating both seizure reduction and seizure‐freedom periods, and examines baseline clinical variables to determine predictors of response. Methods: We retrospectively analyzed all patients prescribed cenobamate from May 2020 to July 2021. The primary outcome was 12‐month seizure frequency reduction for each seizure type, stratified by baseline seizure frequency (higher vs lower frequency: ≥2 seizures vs <2 seizures in the preceding 3 months). Logistic regression identified seizure response predictors. We assessed longest seizure‐free periods, considering seizure type and baseline frequency, further differentiating the higher‐frequency group into weekly and monthly subgroups. We examined retention, safety, and tolerability. Results: Of 182 patients taking cenobamate, 170 had focal epilepsy. Among those 170, the 12‐month retention rate was 82.4%, decreasing to 75% at last follow‐up. In patients with higher‐frequency baseline seizures, ≥50% seizure reduction rates were 47% (95% confidence interval [CI] = 38%–57%) for focal impaired awareness seizures (FIAS) and 58% (95% CI = 43%–71%) for focal to bilateral tonic–clonic seizures (FBTCS). In patients with lower‐frequency seizures, rates were 53% for FIAS (95% CI = 31%–74%) and 68% (95% CI = 49%–82%) for FBTCS. Factors linked to 100% seizure reduction were lower baseline seizure frequency, fewer failed medications, and concomitant clobazam use. Most patients achieving seizure freedom did so at 200 mg/day, although higher doses also showed efficacy, particularly for FBTCS. Among patients with seizures affecting awareness, 7%–43% had ≥12 months of freedom from such seizures. Among patients with FBTCS, 17%–56% had ≥12 months of freedom from FBTCS. Patients with higher‐frequency baseline seizures had lower rates of seizure freedom. Adverse effects were reported by 52%, with drowsiness being most common (32%). One patient developed depression necessitating hospitalization. Significance: Cenobamate is an efficacious drug. Baseline clinical features of seizure type, lower frequency, fewer failed medications, and clobazam use are associated with treatment response and can inform decisions of trialing cenobamate before considering epilepsy surgery.
Real‐world use of cenobamate in adults: Efficacy and predictors of treatment response
Objective: This study assesses the efficacy, safety, and tolerability of cenobamate using long‐term real‐world data, incorporating both seizure reduction and seizure‐freedom periods, and examines baseline clinical variables to determine predictors of response. Methods: We retrospectively analyzed all patients prescribed cenobamate from May 2020 to July 2021. The primary outcome was 12‐month seizure frequency reduction for each seizure type, stratified by baseline seizure frequency (higher vs lower frequency: ≥2 seizures vs <2 seizures in the preceding 3 months). Logistic regression identified seizure response predictors. We assessed longest seizure‐free periods, considering seizure type and baseline frequency, further differentiating the higher‐frequency group into weekly and monthly subgroups. We examined retention, safety, and tolerability. Results: Of 182 patients taking cenobamate, 170 had focal epilepsy. Among those 170, the 12‐month retention rate was 82.4%, decreasing to 75% at last follow‐up. In patients with higher‐frequency baseline seizures, ≥50% seizure reduction rates were 47% (95% confidence interval [CI] = 38%–57%) for focal impaired awareness seizures (FIAS) and 58% (95% CI = 43%–71%) for focal to bilateral tonic–clonic seizures (FBTCS). In patients with lower‐frequency seizures, rates were 53% for FIAS (95% CI = 31%–74%) and 68% (95% CI = 49%–82%) for FBTCS. Factors linked to 100% seizure reduction were lower baseline seizure frequency, fewer failed medications, and concomitant clobazam use. Most patients achieving seizure freedom did so at 200 mg/day, although higher doses also showed efficacy, particularly for FBTCS. Among patients with seizures affecting awareness, 7%–43% had ≥12 months of freedom from such seizures. Among patients with FBTCS, 17%–56% had ≥12 months of freedom from FBTCS. Patients with higher‐frequency baseline seizures had lower rates of seizure freedom. Adverse effects were reported by 52%, with drowsiness being most common (32%). One patient developed depression necessitating hospitalization. Significance: Cenobamate is an efficacious drug. Baseline clinical features of seizure type, lower frequency, fewer failed medications, and clobazam use are associated with treatment response and can inform decisions of trialing cenobamate before considering epilepsy surgery.
- 27 June 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 96 (2) , 356-364
A Speech Neuroprosthesis in the Frontal Lobe and Hippocampus: Decoding High-Frequency Activity into Phonemes
BACKGROUND AND OBJECTIVES: Loss of speech due to injury or disease is devastating. Here, we report a novel speech neuroprosthesis that artificially articulates building blocks of speech based on high-frequency activity in brain areas never harnessed for a neuroprosthesis before: anterior cingulate and orbitofrontal cortices, and hippocampus. METHODS: A 37-year-old male neurosurgical epilepsy patient with intact speech, implanted with depth electrodes for clinical reasons only, silently controlled the neuroprosthesis almost immediately and in a natural way to voluntarily produce 2 vowel sounds. RESULTS: During the first set of trials, the participant made the neuroprosthesis produce the different vowel sounds artificially with 85% accuracy. In the following trials, performance improved consistently, which may be attributed to neuroplasticity. We show that a neuroprosthesis trained on overt speech data may be controlled silently. CONCLUSION: This may open the way for a novel strategy of neuroprosthesis implantation at earlier disease stages (eg, amyotrophic lateral sclerosis), while speech is intact, for improved training that still allows silent control at later stages. The results demonstrate clinical feasibility of direct decoding of high-frequency activity that includes spiking activity in the aforementioned areas for silent production of phonemes that may serve as a part of a neuroprosthesis for replacing lost speech control pathways.
- 27 June 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 96 (2) , 356-364
A Speech Neuroprosthesis in the Frontal Lobe and Hippocampus: Decoding High-Frequency Activity into Phonemes
BACKGROUND AND OBJECTIVES: Loss of speech due to injury or disease is devastating. Here, we report a novel speech neuroprosthesis that artificially articulates building blocks of speech based on high-frequency activity in brain areas never harnessed for a neuroprosthesis before: anterior cingulate and orbitofrontal cortices, and hippocampus. METHODS: A 37-year-old male neurosurgical epilepsy patient with intact speech, implanted with depth electrodes for clinical reasons only, silently controlled the neuroprosthesis almost immediately and in a natural way to voluntarily produce 2 vowel sounds. RESULTS: During the first set of trials, the participant made the neuroprosthesis produce the different vowel sounds artificially with 85% accuracy. In the following trials, performance improved consistently, which may be attributed to neuroplasticity. We show that a neuroprosthesis trained on overt speech data may be controlled silently. CONCLUSION: This may open the way for a novel strategy of neuroprosthesis implantation at earlier disease stages (eg, amyotrophic lateral sclerosis), while speech is intact, for improved training that still allows silent control at later stages. The results demonstrate clinical feasibility of direct decoding of high-frequency activity that includes spiking activity in the aforementioned areas for silent production of phonemes that may serve as a part of a neuroprosthesis for replacing lost speech control pathways.
- Open Access
Cannabidiol‐enriched oil for adult patients with drug‐resistant epilepsy: Prospective clinical and electrophysiological study
Objective: Cannabidiol‐enriched oil (CBDO) is being used increasingly to improve seizure control in adult patients with drug‐resistant epilepsy (DRE), despite the lack of large‐scale studies supporting its efficacy in this patient population. We aimed to assess the effects of add‐on CBDO on seizure frequency as well as on gait, cognitive, affective, and sleep‐quality metrics, and to explore the electrophysiological changes in responder and non‐responder DRE patients treated with add‐on CBDO.Methods: We prospectively recruited adult DRE patients who were treated with add‐on CBDO. Patients were evaluated prior to treatment and following 4 weeks of a maintenance daily dose of ≈260 mg CBD and ≈12 mg Δ9‐tetrahydrocannabinol (THC). The outcome measures included seizure response to CBDO (defined as ≥50% decrease in seizures compared to pre‐CBDO baseline), gait testing, Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS), and sleep‐quality questionnaire assessments. Patients underwent electroencephalography (EEG) recording during rest as well as event‐related potentials (ERPs) during visual Go/NoGo task while sitting and while walking.Results: Nineteen patients were recruited, of which 16 finished pre‐ and post‐CBDO assessments. Seven patients (43.75%) were responders demonstrating an average reduction of 82.4% in seizures, and nine patients (56.25%) were non‐responders with an average seizure increase of 30.1%. No differences in demographics and clinical parameters were found between responders and non‐responders at baseline. However, responders demonstrated better performance in the dual‐task walking post‐treatment (p = .015), and correlation between increase in MoCA and seizure reduction (r = .810, p = .027). Post‐CBDO P300 amplitude was lower during No/Go‐sitting in non‐responders (p = .028) and during No/Go‐walking in responders (p = .068).Significance: CBDO treatment can reduce seizures in a subset of patients with DRE, but could aggravate seizure control in a minority of patients; yet we found no specific baseline clinical or electrophysiological characteristics that are associated with response to CBDO. However, changes in ERPs in response to treatment could be a promising direction to better identify patients who could benefit from CBDO treatment.
Open AccessCannabidiol‐enriched oil for adult patients with drug‐resistant epilepsy: Prospective clinical and electrophysiological study
Objective: Cannabidiol‐enriched oil (CBDO) is being used increasingly to improve seizure control in adult patients with drug‐resistant epilepsy (DRE), despite the lack of large‐scale studies supporting its efficacy in this patient population. We aimed to assess the effects of add‐on CBDO on seizure frequency as well as on gait, cognitive, affective, and sleep‐quality metrics, and to explore the electrophysiological changes in responder and non‐responder DRE patients treated with add‐on CBDO.Methods: We prospectively recruited adult DRE patients who were treated with add‐on CBDO. Patients were evaluated prior to treatment and following 4 weeks of a maintenance daily dose of ≈260 mg CBD and ≈12 mg Δ9‐tetrahydrocannabinol (THC). The outcome measures included seizure response to CBDO (defined as ≥50% decrease in seizures compared to pre‐CBDO baseline), gait testing, Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS), and sleep‐quality questionnaire assessments. Patients underwent electroencephalography (EEG) recording during rest as well as event‐related potentials (ERPs) during visual Go/NoGo task while sitting and while walking.Results: Nineteen patients were recruited, of which 16 finished pre‐ and post‐CBDO assessments. Seven patients (43.75%) were responders demonstrating an average reduction of 82.4% in seizures, and nine patients (56.25%) were non‐responders with an average seizure increase of 30.1%. No differences in demographics and clinical parameters were found between responders and non‐responders at baseline. However, responders demonstrated better performance in the dual‐task walking post‐treatment (p = .015), and correlation between increase in MoCA and seizure reduction (r = .810, p = .027). Post‐CBDO P300 amplitude was lower during No/Go‐sitting in non‐responders (p = .028) and during No/Go‐walking in responders (p = .068).Significance: CBDO treatment can reduce seizures in a subset of patients with DRE, but could aggravate seizure control in a minority of patients; yet we found no specific baseline clinical or electrophysiological characteristics that are associated with response to CBDO. However, changes in ERPs in response to treatment could be a promising direction to better identify patients who could benefit from CBDO treatment.
- Open Access
Therapeutic drug monitoring in pregnancy: Levetiracetam
Objective: Levetiracetam (LEV) is an antiseizure medication that is mainly excreted by the kidneys. Due to its low teratogenic risk, LEV is frequently prescribed for women with epilepsy (WWE). Physiological changes during gestation affect the pharmacokinetic characteristics of LEV. The goal of our study was to characterize the changes in LEV clearance during pregnancy and the postpartum period, to better plan an LEV dosing paradigm for pregnant women.Methods: This retrospective observational study incorporated a cohort of women who were followed up at the epilepsy in pregnancy clinic at Tel Aviv Sourasky Medical Center during the years 2020–2023. Individualized target concentrations of LEV and an empirical postpartum taper were used for seizure control and to reduce toxicity likelihood. Patient visits took place every 1–2 months and included a review of medication dosage, trough LEV blood levels, week of gestation and LEV dose at the time of level measurement, and seizure diaries. Total LEV concentration/dose was calculated based on LEV levels and dose as an estimation of LEV clearance.Results: A total of 263 samples were collected from 38 pregnant patients. We observed a decrease in LEV concentration/dose (C/D) as the pregnancy progressed, followed by an abrupt postpartum increase. Compared to the 3rd trimester, the most significant C/D decrease was observed at the 1st trimester (slope = .85), with no significant change in the 2nd trimester (slope = .11). A significant increase in C/D occurred postpartum (slope = 5.23). LEV dose was gradually increased by 75% during pregnancy compared to preconception. Average serum levels (μg/mL) decreased during pregnancy. During the postpartum period, serum levels increased, whereas the LEV dose was decreased by 24%, compared to the 3rd trimester.Significance: LEV serum level monitoring is essential for WWE prior to and during pregnancy as well as postpartum. Our data contribute to determining a rational treatment and dosing paradigm for LEV use during both pregnancy and the postpartum period.
Open AccessTherapeutic drug monitoring in pregnancy: Levetiracetam
Objective: Levetiracetam (LEV) is an antiseizure medication that is mainly excreted by the kidneys. Due to its low teratogenic risk, LEV is frequently prescribed for women with epilepsy (WWE). Physiological changes during gestation affect the pharmacokinetic characteristics of LEV. The goal of our study was to characterize the changes in LEV clearance during pregnancy and the postpartum period, to better plan an LEV dosing paradigm for pregnant women.Methods: This retrospective observational study incorporated a cohort of women who were followed up at the epilepsy in pregnancy clinic at Tel Aviv Sourasky Medical Center during the years 2020–2023. Individualized target concentrations of LEV and an empirical postpartum taper were used for seizure control and to reduce toxicity likelihood. Patient visits took place every 1–2 months and included a review of medication dosage, trough LEV blood levels, week of gestation and LEV dose at the time of level measurement, and seizure diaries. Total LEV concentration/dose was calculated based on LEV levels and dose as an estimation of LEV clearance.Results: A total of 263 samples were collected from 38 pregnant patients. We observed a decrease in LEV concentration/dose (C/D) as the pregnancy progressed, followed by an abrupt postpartum increase. Compared to the 3rd trimester, the most significant C/D decrease was observed at the 1st trimester (slope = .85), with no significant change in the 2nd trimester (slope = .11). A significant increase in C/D occurred postpartum (slope = 5.23). LEV dose was gradually increased by 75% during pregnancy compared to preconception. Average serum levels (μg/mL) decreased during pregnancy. During the postpartum period, serum levels increased, whereas the LEV dose was decreased by 24%, compared to the 3rd trimester.Significance: LEV serum level monitoring is essential for WWE prior to and during pregnancy as well as postpartum. Our data contribute to determining a rational treatment and dosing paradigm for LEV use during both pregnancy and the postpartum period.